Skip Navigation


ToxSci Advance Access originally published online on July 29, 2008
Toxicological Sciences 2008 106(1):153-161; doi:10.1093/toxsci/kfn157
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
106/1/153    most recent
kfn157v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Will, Y.
Right arrow Articles by Jessen, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Will, Y.
Right arrow Articles by Jessen, B. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

Yvonne Will*, James A. Dykens{dagger}, Sashi Nadanaciva{ddagger}, Brad Hirakawa{dagger}, Joseph Jamieson{dagger}, Lisa D. Marroquin{dagger}, James Hynes§, Shem Patyna and Bart A. Jessen{dagger},1

* Exploratory Safety Differentiation, Pfizer, Inc., Groton, Connecticut 06340 {dagger} Drug Safety Research and Development, Pfizer, Inc., San Diego, California 92121 {ddagger} MitoSciences, Inc., Eugene, Oregon 97403 § Luxcel Biosciences, Ltd., Lee Maltings, Cork, Ireland Clinical Development Pfizer, Inc., San Diego, California 92121

1 To whom correspondence should be addressed at Drug Safety Research and Development, Pfizer, Inc., 10646 Science Center Drive, San Diego, CA 92121. Fax: (858) 678-8290. E-mail: Bart.Jessen{at}pfizer.com.

Received June 3, 2008; accepted July 21, 2008


   Abstract

Cardiovascular disease has recently been suggested to be a significant complication of cancer treatment with several kinase inhibitors. In some cases, the mechanisms leading to cardiotoxicity are postulated to include mitochondrial dysfunction, either as a primary or secondary effect. Detecting direct effects on mitochondrial function, such as uncoupling of oxidative phosphorylation or inhibition of electron transport chain components, as well as identifying targets within the mitochondrial electron transport chain, can be accomplished in vitro. Here, we examined the effects of the tyrosine kinase inhibitor drugs imatinib, dasatinib, sunitinib, and sorafenib on ATP content in H9c2 cells grown under conditions where cells are either glycolytically or aerobically poised. Furthermore, we measured respiratory capacity of isolated rat heart mitochondria in the presence of the four kinase inhibitors and examined their effect on each of the oxidative phosphorylation complexes. Of the four kinase inhibitors examined, only sorafenib directly impaired mitochondrial function at clinically relevant concentrations, potentially contributing to the cytotoxic effect of the drug. For the other three kinase inhibitors lacking direct mitochondrial effects, altered kinase and other signaling pathways, are a more reasonable explanation for potential toxicity.

Key Words: mitochondria; kinase; cytotoxicity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.